CSF2 and melanoma: Another phase I clinical trial aimed to investigate the safety and efficacy of intratumorally applied SAR441000, delivering mRNA species that encode IL-12, interferon-α, GM-CSF, and IL-15, in combination with the PD-1 blocking antibody cemiplimab for patients with melanoma, breast cancer and other skin cancers (NCT03871348).